Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average - Here's Why

Key Points

• Shares crossed above the 200‑day moving average: Arbutus climbed above its 200‑day MA of $4.40, trading as high as $4.77 and last at $4.72 on volume of about 1.51 million shares.
• Analyst and valuation snapshot: coverage is mixed with an average rating of "Hold" and an average price target of $5.00 (one Buy, one Sell), the company has a market cap of roughly $908 million and a negative P/E of -20.52.
• Company focus: Arbutus is a clinical‑stage biopharma developing HBV therapies — including RNAi candidates and next‑generation capsid assembly modulators — and leverages lipid nanoparticle (LNP) delivery technology.

Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.40 and traded as high as $4.77. Arbutus Biopharma shares last traded at $4.72, with a volume of 1,510,052 shares trading hands.

Analyst Ratings Changes

ABUS has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arbutus Biopharma in a research note on Wednesday, January 21st. Wall Street Zen cut Arbutus Biopharma from a "buy" rating to a "hold" rating in a report on Saturday, November 15th. Finally, Chardan Capital restated a "buy" rating and set a $5.00 target price on shares of Arbutus Biopharma in a research report on Friday, November 14th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $5.00.

Arbutus Biopharma Price Performance

The company has a market capitalization of $907.75 million, a P/E ratio of -20.52 and a beta of 0.69. The business's 50-day moving average price is $4.37 and its two-hundred day moving average price is $4.40.

Institutional Investors Weigh In On Arbutus Biopharma

Several large investors have recently modified their holdings of ABUS. Mercer Global Advisors Inc. ADV raised its position in shares of Arbutus Biopharma by 9.2% during the third quarter. Mercer Global Advisors Inc. ADV now owns 38,959 shares of the biopharmaceutical company's stock worth $177,000 after purchasing an additional 3,280 shares during the period. ProShare Advisors LLC grew its position in shares of Arbutus Biopharma by 10.5% in the 4th quarter. ProShare Advisors LLC now owns 36,161 shares of the biopharmaceutical company's stock valued at $174,000 after purchasing an additional 3,446 shares during the period. The Manufacturers Life Insurance Company increased its stake in Arbutus Biopharma by 6.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 59,350 shares of the biopharmaceutical company's stock worth $183,000 after purchasing an additional 3,540 shares in the last quarter. Rhumbline Advisers increased its stake in Arbutus Biopharma by 1.9% during the 3rd quarter. Rhumbline Advisers now owns 211,784 shares of the biopharmaceutical company's stock worth $961,000 after purchasing an additional 3,979 shares in the last quarter. Finally, Rafferty Asset Management LLC raised its holdings in Arbutus Biopharma by 6.7% during the 2nd quarter. Rafferty Asset Management LLC now owns 88,454 shares of the biopharmaceutical company's stock worth $273,000 after buying an additional 5,590 shares during the period. 43.79% of the stock is currently owned by institutional investors.

About Arbutus Biopharma

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company's pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.